Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New market study, "Victrelis (Hepatitis C Virus) - Forecast and Market Analysis to 2022", has been published


Print article Print article
2013-08-06 09:43:35 - New Pharmaceuticals market report from GlobalData: "Victrelis (Hepatitis C Virus) - Forecast and Market Analysis to 2022"

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche's Pegasys and Merck's PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are used to treat HCV infection.

Full Report Details at
- www.fastmr.com/prod/666329_victrelis_hepatitis_c_virus_forecast_ ..

Victrelis is an anti-HCV drug marketed by Merck. Victrelis inhibits the HCV NS3/4A protease by reversibly binding to enzyme's active site. The HCV protease is required for viral polyprotein processing, which makes the enzyme essential for HCV replication

(Asselah and Marcellin, 2013). The HCV protease is, therefore, an attractive drug target. Victrelis was a first-in-class DAA when it was approved in the US and EU in 2011 for the treatment of HCV GT1 infection.

Scope

* Overview of Hepatitis C infection, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Victrelis including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Victrelis for the top nine countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis C
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Victrelis performance
* Obtain sales forecast for Victrelis from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Referral Overview
4.2 Treatment Overview
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Victrelis (boceprevir)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Percent Drug-Treated Patients
7.4.2 Patient Warehousing
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.4.5 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.5.1 Survey of Prescribing Physicians
7.6 About the Authors
7.6.1 Author
7.6.2 Global Head of Healthcare
7.7 About GlobalData
7.8 Contact Us
7.9 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Modes of HCV Transmission
Table 2: Symptoms of Acute and Chronic HCV Infection
Table 3: HCV Genotypes Present in the 9MM
Table 4: General Standard of Care by HCV Genotype
Table 5: Treatment Guidelines for HCV by Country
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013
Table 7: Leading Treatments for HCV, 2012
Table 8: Product Profile - Victrelis
Table 9: Victrelis Efficacy in Treatment-Naive Patients (SPRINT-2 Trial)
Table 10: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial)
Table 11: Victrelis SWOT Analysis, 2012
Table 12: Global Sales Forecasts ($m) for Victrelis, 2012-2022
Table 13: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: HCV Genome and Polyprotein Composition
Figure 2: HCV Lifecycle Overview

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com